The management impact of (68)gallium-tris(hydroxypyridinone) prostate-specific membrane antigen ((68)Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer

PURPOSE: To determine the impact on clinical management of patients with high-risk (HR) prostate cancer at diagnosis and patients with biochemical recurrence (BCR) using a new kit form of (68)Ga-prostate-specific membrane antigen (PSMA), namely tris(hydroxypyridinone) (THP)-PSMA, with positron emiss...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Nucl Med Mol Imaging
Prif Awduron: Kulkarni, Meghana, Hughes, Simon, Mallia, Andrew, Gibson, Victoria, Young, Jennifer, Aggarwal, Ajay, Morris, Stephen, Challacombe, Ben, Popert, Rick, Brown, Christian, Cathcart, Paul, Dasgupta, Prokar, Warbey, Victoria S., Cook, Gary J. R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2019
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7005085/
https://ncbi.nlm.nih.gov/pubmed/31872280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04643-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg